IronOak Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

IronOak Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$623K	Buy	+1,546	New	+$717K	0.7%	47

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

IronOak Wealth's VRTX Position: Q4 2024 in Review

IronOak Wealth opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2024: 1,546 shares worth $623K. The stake represents 0.7% of the portfolio and ranks #47 among its holdings.

1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

IronOak Wealth held 1,546 shares of Vertex Pharmaceuticals worth $623K as of Q4 2024.
Vertex Pharmaceuticals was a new IronOak Wealth position in Q4 2024.
Vertex Pharmaceuticals made up 0.7% of IronOak Wealth's portfolio in Q4 2024, its #47 holding.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on IronOak Wealth's 13F filing for Q4 2024, filed 6 Mar 2025.